-
Subject Areas on Research
-
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
-
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
-
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
-
A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.
-
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
-
A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
-
Active scaffolds for on-demand drug and cell delivery.
-
Acute myelogenous leukemia associated with Ollier disease.
-
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
-
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
-
Atp-bound topoisomerase ii as a target for antitumor drugs.
-
Cardiac evaluation of mitoxantrone.
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
-
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
-
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
-
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
-
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
-
Inhibition of DNA helicase II unwinding and ATPase activities by DNA-interacting ligands. Kinetics and specificity.
-
Intensive single-agent mitoxantrone for metastatic breast cancer.
-
Maintenance therapy in childhood acute myeloid leukemia.
-
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
-
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
-
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
-
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.
-
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
-
Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma.
-
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
-
Phase I-II trial of mitoxantrone in acute leukemia: an interim report.
-
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
-
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
-
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
-
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
-
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
-
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
-
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
-
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
-
Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer.
-
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
-
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
-
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
-
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
-
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
-
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
-
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
-
Update in the management of patients with hormone-refractory prostate cancer.
-
Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
-
Keywords of People